1. New agents in renal cell carcinoma

   • Raetasha Dabney
   • Ryan Devine
   • Benjamin George

   Review 16 November 2013 Pages: 183 - 193

2. Pulmonary complications with the use of mTOR inhibitors in targeted cancer therapy: a systematic review and meta-analysis

   • Benjamin A. Gartrell
   • Jian Ying
   • Matthew D. Galsky

   Original Research 13 July 2013 Pages: 195 - 204

   

3. EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan

   • Fotios Loupakis
   • Chiara Cremolini
   • Guido Bocci

   Original Research 03 July 2013 Pages: 205 - 214

   

4. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors

   • M. Mita
   • M. Gordon
   • D. Mendelson

   Original Research 06 July 2013 Pages: 215 - 224

   

5. In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC

   • Maryam Nourizadeh
   • Farimah Masoumi
   • Jamshid Hadjati

   Original Research 14 July 2013 Pages: 225 - 237

   

6. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma

   • Nate N. Waldron
   • Sanford H. Barsky
   • Daniel A. Vallera

   Original Research 31 July 2013 Pages: 239 - 249

   

7. Recombinant TIMP-1-GPI inhibits growth of fibrosarcoma and enhances tumor sensitivity to doxorubicin

   • Q. Bao
   • H. Niess
   • C. J. Bruns

   Original Research Open access 10 August 2013 Pages: 251 - 261

   

8. Anti-Sp17 monoclonal antibody–doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma

   • Jia-Xi Song
   • Fang-Qiu Li
   • Qian-Qian Kong

   Original Research 14 August 2013 Pages: 263 - 272

   

9. Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial

   • Nicolas Penel
   • Isabelle Ray-Coquard
   • Charles Fournier

   Original Research 12 November 2013 Pages: 273 - 277

   

10. Curcumin induces apoptosis of HepG2 cells via inhibiting fatty acid synthase

    • Huijin Fan
    • Weixi Tian
    • Xiaofeng Ma

    Original Research 03 July 2013 Pages: 279 - 286

    

11. Diagnostic challenges of respiratory adverse events during everolimus treatment

    • Annelieke E. C. A. B. Willemsen
    • Filip Y. De Vos
    • Carla M. L. van Herpen

    Day-to-Day Practice 05 March 2014 Pages: 287 - 291